Progenics Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tarrytown NY United States (1986)
Status: Acquired by Lantheus Medical Imaging (2019)

Organization Overview

First Clinical Trial
2002
NCT01367574
First Marketed Drug
2008
methylnaltrexone (relistor)
First NDA Approval
2008
methylnaltrexone (relistor)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Progenics Pharmaceuticals, Inc. | PROGENICS PHARMS INC | Vice President, Clinical Research, Progenics Pharmaceuticals, Inc.